Zobrazeno 1 - 10
of 84
pro vyhledávání: '"T. P. Beketova"'
Autor:
T. V. Beketova
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 5, Pp 531-536 (2023)
The new 2022 classification criteria for antineutrophil cytoplasmic antibodies associated vasculitis (AAV), proposed by the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR), was an important st
Externí odkaz:
https://doaj.org/article/bfae3ac9ce954c4dbf353072dcfd9bee
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 4, Pp 458-465 (2023)
The article is dedicated to a new actual problem in rheumatology: vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes in adult. The features of the clinical course of the rarely diagnosed VEXAS syndrome, as well as t
Externí odkaz:
https://doaj.org/article/4e043141352b436891e31e8f4161bdd0
Autor:
T. V. Beketova
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 3, Pp 385-388 (2023)
Susac syndrome (SS) or retino-cochleo-cerebral vasculopathy is an extremely rare, severe, and potentially disabling condition. Underlying occlusive microangiopathy in SS is clinically characterized by the triad of encephalopathy, sensorineural hearin
Externí odkaz:
https://doaj.org/article/561390e1e36d48da8432b0caaf179d2f
Autor:
T. V. Beketova, N. О. Levina, M. V. Dubinskaia, Yu. A. Uskova, I. V. Rozanova, V. V. Babak, M. F. Beketova, T. N. Krasnova
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 2, Pp 158-164 (2023)
The problem of prevention of coronavirus disease 2019 (COVID-19) in patients with immune-mediated inflammatory rheumatic diseases (IMRD) remains highly relevant. The presence of IRD is associated with a high risk of disease and severe course of COVID
Externí odkaz:
https://doaj.org/article/2407dd9544ae46f09d4abf73ddbb5651
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 1, Pp 62-69 (2023)
Depending on the epitope specificity of antineutrophil cytoplasmic antibodies (ANCA) and the presence or absence of a granulomatous inflammation. Patients with ANCA-associated vasculitis (AAV) show variability in clinical manifestations and prognosis
Externí odkaz:
https://doaj.org/article/b92dbf8073dc42259430ea84fdca767c
Autor:
E. F. Iskhakova, E. V. Sukhorukova, M. Yu. Badeeva, E. V. Dyakova, S. A. Lapshina, T. V. Beketova, D. I. Abdulganieva
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 1, Pp 42-46 (2023)
Patients with ANCA-associated vasculitis (AAV) cause extreme alertness during the coronavirus disease 2019 (COVID-19) pandemic, associated with many factors: the initial damage to the respiratory system (upper respiratory tract, lungs) and kidneys, i
Externí odkaz:
https://doaj.org/article/fa1513727adc4d828d06c4b371a87a4e
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 4, Pp 420-426 (2022)
Coronavirus disease 2019 (COVID-19) can manifest with a wide range of extrapulmonary symptoms and have longterm consequences (so-called post-covid syndrome (PCS) or “long COVID-19”). Manifestations of PCS show a wide clinical spectrum and include
Externí odkaz:
https://doaj.org/article/065110f7652647318f098a09b4a5bf2e
Publikováno v:
Oftalʹmologiâ, Vol 19, Iss 2, Pp 452-457 (2022)
The World Health Organization announced a new coronavirus pandemic on 11 March 2020. It is known that the most frequent clinical manifestation of a new coronavirus infection is lung damage with the evolution of pneumonia, as well as respiratory distr
Externí odkaz:
https://doaj.org/article/aad827a74340446bbd83afa4e0faa9cd
Publikováno v:
Современная ревматология, Vol 16, Iss 3, Pp 37-41 (2022)
In the last decade, anti-neutrophil cytoplasmic antibodies (ANCA)-associated systemic vasculitis (SV) has been treated with the anti-B-cell drug, rituximab (RTM) both for induction and maintenance therapy. One of the problems of the treatment with RT
Externí odkaz:
https://doaj.org/article/3127ebbb3a2a4a1db1c7cb5aa81b611d
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 2, Pp 165-173 (2022)
The main statements of the recommendations of the American College of Rheumatology and the Vasculitis Foundation on the treatment of patients with systemic vasculitis of large vessels, published in August 2021, are discussed. As a result of a detaile
Externí odkaz:
https://doaj.org/article/715c31ff14b44a0a9ee061373181f836